参考文献:1.Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRef PubMed 2.Lortet-Tieulent J, Soerjomataram I, Ferlay J et al (2014) International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 84:13–22CrossRef PubMed 3.Nakamura H, Saji H (2014) Worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 44:1004–1012CrossRef PubMed 4.Okada M (2013) Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. Thorac Surg Clin 23:179–186CrossRef PubMed 5.Gu W, Fang S, Gao L et al (2013) Clinic significance of microRNA-99a expression in human lung adenocarcinoma. J Surg Oncol 108:248–255CrossRef PubMed 6.Chen W, Zheng R, Zhang S et al (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32:106–112PubMedCentral CrossRef PubMed 7.Chilosi M, Murer B (2010) Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med 134:55–65PubMed 8.Nielsen J, Christiansen J, Lykke-Andersen J et al (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19:1262–1270PubMedCentral CrossRef PubMed 9.Liao B, Hu Y, Brewer G (2011) RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem 286:31145–31152PubMedCentral CrossRef PubMed 10.Findeis-Hosey JJ, Xu H (2011) The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 42:303–314CrossRef PubMed 11.Sitnikova L, Mendese G, Liu Q et al (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14:1701–1706CrossRef PubMed 12.Jiang Z, Lohse CM, Chu PG et al (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112:2676–2682PubMedCentral CrossRef PubMed 13.Hoffmann NE, Sheinin Y, Lohse CM et al (2008) External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112:1471–1479PubMedCentral CrossRef PubMed 14.Zheng W, Yi X, Fadare O et al (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32:304–315CrossRef PubMed 15.Wei Q, Yan J, Fu B et al (2014) IMP3 expression is associated with poor survival in cervical squamous cell carcinoma. Hum Pathol 45:2218–2224CrossRef PubMed 16.Vikesaa J, Hansen TV, Jonson L et al (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25:1456–1468PubMedCentral CrossRef PubMed 17.Bell JL, Wachter K, Muhleck B et al (2013) Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70:2657–2675PubMedCentral CrossRef PubMed 18.Hwang YS, Xianglan Z, Park KK et al (2012) Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression. Carcinogenesis 33:2135–2146CrossRef PubMed 19.Findeis-Hosey JJ, Yang Q, Spaulding BO et al (2010) IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 41:477–484CrossRef PubMed 20.Yuan RH, Wang CC, Chou CC et al (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16:1711–1719CrossRef PubMed 21.Li D, Yan D, Tang H et al (2009) IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16:3499–3506CrossRef PubMed 22.Gong Y, Woda BA, Jiang Z (2014) Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol 21:191–200CrossRef PubMed 23.Bellezza G, Cavaliere A, Sidoni A (2009) IMP3 expression in non-small cell lung cancer. Hum Pathol 40:1205–1206CrossRef PubMed 24.Beljan PR, Durdov MG, Capkun V et al (2012) IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 7:165CrossRef 25.Dhwc S (2002) International union against cancer (UICC): TNM classification of malignant tumors. Wiley, New York 26.Travis WD, Brambilla E, Müller-Hermelink HK et al. (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart, vol 10. Lyon: IARC Press. World Health Organization Classification of Tumors 27.Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402–408CrossRef PubMed 28.Mueller-Pillasch F, Lacher U, Wallrapp C et al (1997) Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14:2729–2733CrossRef PubMed 29.Jiang Z, Chu PG, Woda BA et al (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7:556–564CrossRef PubMed 30.Zheng W, Yi X, Fadare O et al (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32:304–315CrossRef PubMed 31.Yuan RH, Wang CC, Chou CC et al (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16:1711–1719CrossRef PubMed 32.Liao B, Hu Y, Herrick DJ et al (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280:18517–18524CrossRef PubMed 33.Jeng YM, Chang CC, Hu FC et al (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48:1118–1127CrossRef PubMed 34.Findeis-Hosey JJ, Xu H (2012) Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 87:24–29CrossRef PubMed 35.Pasiliao CC, Chang CW, Sutherland BW et al (2015) The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer 15:266PubMedCentral CrossRef PubMed 36.Rivera VT, Boudoukha S, Simon A et al (2014) Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization. Oncogene 33:2866–2875CrossRef 37.Su P, Hu J, Zhang H et al (2014) IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer. Int J Clin Exp Pathol 7:3008–3017PubMedCentral PubMed 38.Nemunaitis J, Meyers T, Senzer N et al (2006) Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Therapy 13:1185–1191CrossRef
作者单位:Jinhai Yan (1) (2) Qingzhu Wei (3) Wenjing Jian (1) Bo Qiu (1) Jing Wen (1) Jianghuan Liu (3) Bo Fu (3) Xinhua Zhou (1) Tong Zhao (3)
1. Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou, China 2. Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 3. Department of Pathology, The Third Affiliated Hospital of Southern Medical University, Zhongshan Dadaoxi, Street No. 183, Guangzhou, 510630, China
刊物类别:Medicine
刊物主题:Medicine & Public Health Pneumology and Respiratory System
出版者:Springer New York
ISSN:1432-1750
文摘
Purpose Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein associated with several aggressive and advanced cancers. Whether IMP3 can predict invasion, and prognosis in patients with human lung adenocarcinoma (LAC) remains unclear.